BiotechTube
Palm Therapeutics

Palm Therapeutics

San Diego, United States· Est.
palmtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8M

Overview

Palm Therapeutics is an early-stage biotech focused on the novel therapeutic target of protein palmitoylation, leveraging its exclusive PalmReader screening platform to accelerate drug discovery. The company has gained significant recognition through awards and grants, including from Curebound, Servier, and California Life Sciences, and has secured venture investment from Tachyon Ventures. Operating in a nascent but promising field, Palm is positioned as a first-mover in developing palmitoylation-targeted small molecule therapeutics, though its pipeline remains in the discovery or preclinical stages.

Small Molecules

Technology Platform

PalmReader - a proprietary high-throughput screening platform for detecting and quantifying protein palmitoylation, enabling the rapid identification of small molecule modulators of this post-translational modification.

Funding History

1
Total raised:$2.8M
Seed$2.8M

Opportunities

As a first-mover in palmitoylation-targeted drug discovery, Palm has the opportunity to define and dominate a novel therapeutic modality with applicability across a wide range of diseases involving misregulated protein localization and signaling.
Its PalmReader platform also presents significant partnership and licensing potential with larger pharmaceutical companies seeking to drug challenging targets.

Risk Factors

The core risk is the unproven therapeutic hypothesis that palmitoylation can be selectively and safely modulated with small molecules in humans.
The company also faces significant technical hurdles in converting platform hits into viable drug candidates, intense competition for funding, and the long, costly path of drug development with no clinical-stage assets.

Competitive Landscape

Direct competition in palmitoylation-targeted small molecule drug discovery appears minimal, positioning Palm as a pioneer. However, indirect competition exists from companies targeting related post-translational modifications (e.g., phosphorylation, ubiquitination) and from broader drug discovery platforms. The field is nascent, but success by Palm would likely attract rapid entry from well-capitalized biotechs and pharma.

More companies in Small Molecule Drugs →More companies in United States →